Crunching the numbers for SPRY... Refresh in a moment for the full analysis.
ARS Pharmaceuticals, Inc. (SPRY)
weak
$8.05
Updated: 2026-04-13
38
TradeApes Score
reduce
Financial Strength
55
Mixed
Operating Trend
10
Stressed
Valuation
50
Mixed
Capital Allocation
30
Weak
Risk
50
Mixed
Key Findings
+
Net cash position — more cash on hand than total debt
−
Sharp revenue decline — sales down more than 15% year over year
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Add to Watchlist
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.